MedTrace Logo

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

NCT00646529 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2009-03-30

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of Symbicort compared to Pulmicort in asthmatic children aged 6 to 11 years

Conditions

Interventions

DRUG

budesonide/formoterol (Symbicort)

DRUG

budesonide (Pulmicort)

Sponsors & Collaborators

Principal Investigators

  • Catherine Bonuccelli · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2003-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646529 on ClinicalTrials.gov